Enlivex: Jumps on Canadian patent for potential COVID-19 treatment

Enlivex

01/06/2021 16:14

** U.S.-listed shares of Israel-based drug developer Enlivex
Therapeutics  ENLV.O  rise 5.7% to $9.9
    ** Canadian Intellectual Property Office issues new patent
for co's experimental therapy, Allocetra  urn:newsml:reuters.com:*:nGNX4r51sD
    ** ENLV is testing Allocetra in severe and critical COVID-19
patients as well as patients with organ failure associated with
sepsis
    ** Patent is expected to provide added IP protection for
pharmaceutical compositions, manufacturing methods and uses of
Allocetra - ENLV
    ** Shares jumped as much as 30% on Feb. 3 after co said 14
of 16 COVID-19 patients treated with Allocetra in a mid-stage
trial recovered completely and were discharged from hospital
 urn:newsml:reuters.com:*:nL4N2K93RB
    ** U.S.-listed ENLV shares up ~18% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))